A Phase 1 interventional study of GSK3882347 and Nitrofurantoin in Uncomplicated Urinary Tract Infections and Urinary Tract Infections, sponsored by GlaxoSmithKline. Completed at 15 sites in United States. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Urinary Tract Infections by GlaxoSmithKline — 4 open to participants now, 4 under way, none of them phase 3. Urinary Tract Infections · GlaxoSmithKline.
Among the 14 studies in Urinary Tract Infections by GlaxoSmithKline, this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2022, is one of 5 in phase 1, and was the 7th registered.
804 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.
Browse Urinary Tract Infections studies →4 of the 14 studies in Urinary Tract Infections by GlaxoSmithKline are open now, in 2 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
GlaxoSmithKline · Sites in United States, South Africa
Ages 18–64 · Healthy volunteers
GlaxoSmithKline
Ages 15–50 · Women only
GlaxoSmithKline · Sites in United States
Ages 2–11
By country, each count listing its studies:
Of the 84 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (27%) stop at 75 or younger; 15 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 3 · Phase 3 4 · Phase 4 1
First in 2011; this study’s year is marked. 1 started in 2022.
This study's enrollment of 140 is close to the median of 132 across 561 interventional studies indexed under Urinary Tract Infections.
Median enrollment 61 across the 13 interventional studies, 614 across the 1 observational. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
3 of the studies in Urinary Tract Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07645235GlaxoSmithKlineA Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating Women | 2027-05-17 |
| NCT06702449GlaxoSmithKlineA Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age | 2027-05-31 |
| NCT07371429GlaxoSmithKlineA Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics | 2027-08-23 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Urinary Tract Infections by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase 1b study is a double-blind, double-dummy, nitrofurantoin-controlled study designed to evaluate microbiological response at the test of cure (ToC) visit along with safety, tolerability and pharmacokinetic (PK) response following oral dosing for 5 days of GSK3882347 in an adult female with uncomplicated urinary tract infections (uUTI). Comparator nitrofurantoin will be included in the study to ensure unbiased reporting of safety events. The study will be separated into 2 cohorts. Cohort 1 consists of an inpatient treatment period and PK analysis at frequent timepoints. Cohort 2 includes an outpatient treatment period and PK analysis conducted less frequently, at key trough timepoints.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received GSK3882347 oral capsules plus placebo oral capsules from Day 1 to Day 5.
Drug: GSK3882347 · Drug: Placebo
Participants received 100 milligrams (mg) of nitrofurantoin oral capsules plus placebo oral capsules from Day 1 to Day 5.
Drug: Nitrofurantoin · Drug: Placebo
GSK3882347 was administered.
Nitrofurantoin was administered.
Placebo matching GSK3882347 or Nitrofurantoin was administered.
Number of Participants With Microbiological Response at the Test of Cure (ToC) Visit
Microbiological response (success/failure) is used to measure microbiological efficacy. Microbiological success was defined as a reduction in E. coli count to less than (\<) 10\^3 colony-forming units (CFU) per milliliter (CFU/mL) for any E. coli at the ToC visit. Microbiological failure included all other microbiological outcomes (for example but not limited to \>=10\^3 CFU/mL for any E. coli identified at ToC visit, use of rescue medication prior to ToC, lost to follow-up before ToC, missing/unevaluable samples at ToC, etc).
Time frame: Day 10 to Day 13 (ToC Visit)
Number of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
Time frame: From the first dose of study intervention up to Follow-up Visit (up to Day 31)
Number of Participants With Serious AEs (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability or incapacity; is a congenital anomaly or birth defect; or any other situation according to the medical or scientific judgment of the investigator.
Time frame: From the signing of informed consent up to Follow-up Visit (up to Day 31)
Number of Participants With Clinically Significant Changes in Vital Signs Findings
Vital signs included tympanic-measured temperature, pulse and respiratory rate, systolic and diastolic blood pressure. Blood pressure and pulse measurements were assessed in a semi-supine or seated position with a completely automated device and were measured after at least 10 minutes of rest for the participant in a quiet setting without distractions. Clinical significance of any change in vital signs was determined by the investigator.
Time frame: Up to Day 31
Number of Participants With Clinically Significant Changes in Electrocardiograms (ECG) Findings
Twelve-lead ECGs were obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc) intervals. Clinical significance of any change in ECG findings was determined by the investigator.
Time frame: Up to Day 31
Number of Participants With Clinically Significant Changes in Hematology Parameters
Blood samples were collected for hematology parameters including platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, reticulocytes, white blood cell (WBC) count (neutrophils, lymphocytes, monocytes, eosinophils, basophils). Clinical significance of any change in hematology parameters was determined by the investigator.
Time frame: Up to Day 31
Number of Participants With Clinically Significant Changes in Chemistry Parameters
Blood samples were collected for chemistry parameters including blood urea nitrogen (BUN), creatinine (including estimated glomerular filtration rate \[eGFR\]), glucose (non-fasting), potassium, sodium, calcium, total and direct bilirubin, total protein, aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT), and alkaline phosphatase. Clinical significance of any change in clinical chemistry parameters was determined by the investigator.
Time frame: Up to Day 31
Number of Participants With Clinically Significant Changes in Urinalysis Parameters
Urine samples were collected for the analysis of urine parameters including specific gravity, potential of hydrogen (pH), glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase, microscopic examination (if blood or protein was abnormal), and protein/creatinine ratio. Clinical significance of any change in urinalysis parameters was determined by the investigator.
Time frame: Up to Day 31
Cohort 1: Plasma Concentration at the End of the Dosing Interval Tau (Ctau) of GSK3882347 Post-dose on Day 1 and Day 5
Time frame: 24 hours post-dose on Day 1 and Day 5
Cohort 1: Urine Concentration of GSK3882347 at 22-24-hour (h) Interval Collection Post-dose on Day 1 and Day 5
Time frame: 22-24 hour interval post-dose on Day 1 and Day 5
Cohort 2: Plasma Ctau of GSK3882347 Post-dose on Day 1 and Day 5
Time frame: 24 hours post-dose on Day 1 and Day 5
Cohort 2: Urine Concentration of GSK3882347 at 22-24h Interval Collection Post-dose on Day 1 and Day 5
Time frame: 22-24 hour interval post-dose on Day 1 and Day 5
Number of Participants With Clinical Symptom Score Outcome
Clinical symptom score (CSS) measures 4 uncomplicated urinary tract infection (uUTI) symptoms: dysuria, frequency, urgency, and lower abdominal/suprapubic pain. Each symptom is scored from 0 (no symptoms) to 3 (severe). Individual symptom scores are added for a cumulative total score (range 0-12), with higher scores indicating greater severity. Clinical outcome for a visit is categorized based on change of total score from baseline (BL): Clinical Resolution (CR) - Total score decreases from BL to 0; Clinical Improvement (CI) - Total score decreases from BL but is greater than (\>) 0; Clinical Worsening (CW) - Total score increases or has no change from BL; or Indeterminate (Ind) - Participant (par.) failed to attend the visit, achieved CR/CI but received systemic antibacterials between BL and the visit day being assessed, or BL score is missing. For a clinical outcome of CR/CI, the par. must not have received another systemic antibacterials between BL and the visit being assessed.
Time frame: Day 2 to Day 6
Number of Participants With Clinical Symptom Score Response at the ToC Visit
CSS measures 4 uUTI symptoms: dysuria, frequency, urgency, and lower abdominal/suprapubic pain. Each symptom is scored from 0 (no symptoms) to 3 (severe). Individual symptom scores are added for a cumulative total score (range 0-12), with higher scores indicating greater severity. Clinical outcome at ToC is categorized based on change of total score from BL: CR - Total score decreases from BL to 0; CI - Total score decreases from BL but is \>0; CW - Total score increases or has no change from BL; Ind - Par. refused a clinical examination, failed to attend the ToC visit, achieved CR or CI but received another systemic antibacterial before ToC, or BL score is missing. For a clinical outcome of CR or CI, the par. must not have received another systemic antibacterial between BL and ToC visit. Clinical response at ToC is defined as "Clinical Success" for an outcome of CR, and "Clinical Failure" for any other outcome (CI, CW, or Ind).
Time frame: Day 10 to Day 13 (ToC Visit)
Number of Participants With Clinical Symptom Score Response at the Follow-up (FU) Visit
CSS measures 4 uUTI symptoms: dysuria, frequency, urgency, and lower abdominal/suprapubic pain. Individual symptoms (each scored 0 to 3) are added for a total score (0-12), with higher scores indicating greater severity. Clinical outcome at FU is categorized based on change of total score from ToC: Sustained CR (SCR) - ToC and FU=0; Delayed CR (DCR) - FU=0, after \>0 at ToC; CI - Total score at FU and ToC\>0, with score at FU\<ToC; CW - Total score at FU and ToC\>0, with score at FU\>ToC; Clinical Recurrence (CRr) - Total score \>0 at FU after ToC=0; Ind - Par. refused a clinical exam, failed to attend FU, achieved SCR/DCR/CI but received another systemic antibacterials before ToC, or BL score is missing. For a clinical outcome of SCR/DCR/CI, the par. must not have received any systemic antibacterials between BL and FU. Clinical response at FU is defined as "Clinical Success" for an outcome of SCR, and "Clinical Failure" for any other outcome (DCR, CI, CW, CRr, or Ind).
Time frame: Day 25 to Day 31 (Follow-up Visit)
Number of Participants With Clinical Resolution Response Outcome
The investigators were asked to record their impression of the clinical status of the participant with regard to the presenting uUTI (resolved/unresolved). Clinical resolution outcome was reported as Clinically Resolved if, in the opinion of the investigator, there was resolution of signs and symptoms of the uUTI present at Baseline (and no worsening and no new signs and symptoms) and no requirement for the use of other antibacterial therapy. Refusal to consent to a clinical examination at a required in-person visit or failure to attend the visit had an outcome of Indeterminate.
Time frame: Day 2 to Day 6
Number of Participants With Clinical Resolution Response at the ToC Visit
The investigators were asked to record their impression of the clinical status of the participant with regard to the presenting uUTI (resolved/unresolved). Clinical resolution response at ToC visit was defined as "Clinical Resolution Success (CRS)" when, in the opinion of the investigator, there was resolution of signs and symptoms of the uUTI present at Baseline (and no worsening and no new signs and symptoms) and no requirement for the use of other antibacterial therapy. "Clinical Resolution Failure (CRF)" was defined when investigator's assessment was Clinically Unresolved/Clinical Worsening or Indeterminate at ToC. Indeterminate was defined as refusal to consent to a clinical examination or failure to attend the ToC visit.
Time frame: Day 10 to Day 13 (ToC Visit)
Number of Participants With Clinical Resolution Response at the Follow-up (FU) Visit
The investigators were asked to record their impression of the clinical status of the participant with regard to the presenting uUTI (resolved/unresolved). Clinical resolution response at FU was defined as "CRS" when investigator's assessment was Clinically Resolved at both ToC and FU (SCR), i.e., resolution of signs and symptoms of the uUTI present at BL (and no worsening and no new signs and symptoms) and no requirement for the use of other antibacterials. "CRF" was defined when investigator's assessment was: Clinically Unresolved at ToC but Clinically Resolved at FU (DCR); Clinically Resolved at ToC but Clinically Unresolved at FU (CRr); Clinically Unresolved at both ToC and FU (CU/CW); or when participants refused to consent to a clinical exam, failed to attend the FU, or achieved SCR/DCR but received other systemic antibacterials before FU (Ind).
Time frame: Day 25 to Day 31 (Follow-up Visit)
| Milestone | Nitrofurantoin + Placebo | GSK3882347+ Placebo |
|---|---|---|
| Started | 35 | 105 |
| Safety analysis set | 34 | 102 |
| Pharmacokinetic (pk) analysis set | 33 | 99 |
| Microbiological modified per protocol (micro-mpp) analysis set | 11 | 29 |
| Completed | 31 | 94 |
| Not completed | 4 | 11 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol violation | 1 | 8 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 |
Microbiological response (success/failure) is used to measure microbiological efficacy. Microbiological success was defined as a reduction in E. coli count to less than (\<) 10\^3 colony-forming units (CFU) per milliliter (CFU/mL) for any E. coli at the ToC visit. Microbiological failure included all other microbiological outcomes (for example but not limited to \>=10\^3 CFU/mL for any E. coli identified at ToC visit, use of rescue medication prior to ToC, lost to follow-up before ToC, missing/unevaluable samples at ToC, etc).
| Participants | Nitrofurantoin + Placebo | GSK3882347+ Placebo |
|---|---|---|
| Microbiological Success | 10 | 10 |
| Microbiological Failure | 1 | 18 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
| Participants | Nitrofurantoin + Placebo | GSK3882347+ Placebo |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 10 | 22 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability or incapacity; is a congenital anomaly or birth defect; or any other situation according to the medical or scientific judgment of the investigator.
| Participants | Nitrofurantoin + Placebo | GSK3882347+ Placebo |
|---|---|---|
| Number of Participants With Serious AEs (SAEs) | 0 | 0 |
Vital signs included tympanic-measured temperature, pulse and respiratory rate, systolic and diastolic blood pressure. Blood pressure and pulse measurements were assessed in a semi-supine or seated position with a completely automated device and were measured after at least 10 minutes of rest for the participant in a quiet setting without distractions. Clinical significance of any change in vital signs was determined by the investigator.
| Participants | Nitrofurantoin + Placebo | GSK3882347+ Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Vital Signs Findings | 0 | 0 |
Twelve-lead ECGs were obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc) intervals. Clinical significance of any change in ECG findings was determined by the investigator.
| Participants | Nitrofurantoin + Placebo | GSK3882347+ Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Electrocardiograms (ECG) Findings | 0 | 0 |
Blood samples were collected for hematology parameters including platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, reticulocytes, white blood cell (WBC) count (neutrophils, lymphocytes, monocytes, eosinophils, basophils). Clinical significance of any change in hematology parameters was determined by the investigator.
| Participants | Nitrofurantoin + Placebo | GSK3882347+ Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Hematology Parameters | 2 | 2 |
Blood samples were collected for chemistry parameters including blood urea nitrogen (BUN), creatinine (including estimated glomerular filtration rate \[eGFR\]), glucose (non-fasting), potassium, sodium, calcium, total and direct bilirubin, total protein, aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT), and alkaline phosphatase. Clinical significance of any change in clinical chemistry parameters was determined by the investigator.
| Participants | Nitrofurantoin + Placebo | GSK3882347+ Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Chemistry Parameters | 1 | 3 |
Urine samples were collected for the analysis of urine parameters including specific gravity, potential of hydrogen (pH), glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase, microscopic examination (if blood or protein was abnormal), and protein/creatinine ratio. Clinical significance of any change in urinalysis parameters was determined by the investigator.
| Participants | Nitrofurantoin + Placebo | GSK3882347+ Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Urinalysis Parameters | 0 | 0 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Clinical symptom score (CSS) measures 4 uncomplicated urinary tract infection (uUTI) symptoms: dysuria, frequency, urgency, and lower abdominal/suprapubic pain. Each symptom is scored from 0 (no symptoms) to 3 (severe). Individual symptom scores are added for a cumulative total score (range 0-12), with higher scores indicating greater severity. Clinical outcome for a visit is categorized based on change of total score from baseline (BL): Clinical Resolution (CR) - Total score decreases from BL to 0; Clinical Improvement (CI) - Total score decreases from BL but is greater than (\>) 0; Clinical Worsening (CW) - Total score increases or has no change from BL; or Indeterminate (Ind) - Participant (par.) failed to attend the visit, achieved CR/CI but received systemic antibacterials between BL and the visit day being assessed, or BL score is missing. For a clinical outcome of CR/CI, the par. must not have received another systemic antibacterials between BL and the visit being assessed.
| Participants | Nitrofurantoin + Placebo | GSK3882347+ Placebo |
|---|---|---|
| Day 2 - Clinical Resolution (CR) | 0 | 1 |
| Day 2 - Clinical Improvement (CI) | 8 | 19 |
| Day 2 - Clinical Worsening (CW) | 3 | 8 |
| Day 3 - Clinical Improvement (CI) | 2 | 1 |
| Day 4 - Clinical Resolution (CR) | 2 | 5 |
| Day 4 - Clinical Improvement (CI) | 9 | 22 |
| Day 4 - Clinical Worsening (CW) | 0 | 1 |
| Day 5 - Clinical Resolution (CR) | 2 | 1 |
| Day 6 - Clinical Resolution (CR) | 9 | 14 |
| Day 6 - Clinical Improvement (CI) | 2 | 13 |
| Day 6 - Clinical Worsening (CW) | 0 | 1 |
CSS measures 4 uUTI symptoms: dysuria, frequency, urgency, and lower abdominal/suprapubic pain. Each symptom is scored from 0 (no symptoms) to 3 (severe). Individual symptom scores are added for a cumulative total score (range 0-12), with higher scores indicating greater severity. Clinical outcome at ToC is categorized based on change of total score from BL: CR - Total score decreases from BL to 0; CI - Total score decreases from BL but is \>0; CW - Total score increases or has no change from BL; Ind - Par. refused a clinical examination, failed to attend the ToC visit, achieved CR or CI but received another systemic antibacterial before ToC, or BL score is missing. For a clinical outcome of CR or CI, the par. must not have received another systemic antibacterial between BL and ToC visit. Clinical response at ToC is defined as "Clinical Success" for an outcome of CR, and "Clinical Failure" for any other outcome (CI, CW, or Ind).
| Participants | Nitrofurantoin + Placebo | GSK3882347+ Placebo |
|---|---|---|
| Clinical Success | 11 | 21 |
| Clinical Improvement (CI) | 0 | 5 |
| Clinical Worsening (CW) | 0 | 1 |
| Indeterminate (Ind) | 0 | 1 |
CSS measures 4 uUTI symptoms: dysuria, frequency, urgency, and lower abdominal/suprapubic pain. Individual symptoms (each scored 0 to 3) are added for a total score (0-12), with higher scores indicating greater severity. Clinical outcome at FU is categorized based on change of total score from ToC: Sustained CR (SCR) - ToC and FU=0; Delayed CR (DCR) - FU=0, after \>0 at ToC; CI - Total score at FU and ToC\>0, with score at FU\<ToC; CW - Total score at FU and ToC\>0, with score at FU\>ToC; Clinical Recurrence (CRr) - Total score \>0 at FU after ToC=0; Ind - Par. refused a clinical exam, failed to attend FU, achieved SCR/DCR/CI but received another systemic antibacterials before ToC, or BL score is missing. For a clinical outcome of SCR/DCR/CI, the par. must not have received any systemic antibacterials between BL and FU. Clinical response at FU is defined as "Clinical Success" for an outcome of SCR, and "Clinical Failure" for any other outcome (DCR, CI, CW, CRr, or Ind).
| Participants | Nitrofurantoin + Placebo | GSK3882347+ Placebo |
|---|---|---|
| Clinical Success | 10 | 19 |
| Delayed Clinical Resolution (DCR) | 0 | 3 |
| Clinical Improvement (CI) | 0 | 2 |
| Clinical Recurrence (CRr) | 1 | 1 |
| Clinical Worsening (CW) | 0 | 1 |
| Indeterminate (Ind) | 0 | 2 |
The investigators were asked to record their impression of the clinical status of the participant with regard to the presenting uUTI (resolved/unresolved). Clinical resolution outcome was reported as Clinically Resolved if, in the opinion of the investigator, there was resolution of signs and symptoms of the uUTI present at Baseline (and no worsening and no new signs and symptoms) and no requirement for the use of other antibacterial therapy. Refusal to consent to a clinical examination at a required in-person visit or failure to attend the visit had an outcome of Indeterminate.
| Participants | Nitrofurantoin + Placebo | GSK3882347+ Placebo |
|---|---|---|
| Day 2 - Clinically Resolved | 0 | 1 |
| Day 2 - Clinically Unresolved (CU)/Clinical Worsening (CW) | 11 | 27 |
| Day 3 - Clinically Unresolved (CU)/Clinical Worsening (CW) | 2 | 1 |
| Day 4 - Clinically Resolved | 3 | 5 |
| Day 4 - Clinically Unresolved (CU)/Clinical Worsening (CW) | 8 | 23 |
| Day 5 - Clinically Resolved | 2 | 1 |
| Day 6 - Clinically Resolved | 9 | 15 |
| Day 6 - Clinically Unresolved (CU)/Clinical Worsening (CW) | 2 | 13 |
The investigators were asked to record their impression of the clinical status of the participant with regard to the presenting uUTI (resolved/unresolved). Clinical resolution response at ToC visit was defined as "Clinical Resolution Success (CRS)" when, in the opinion of the investigator, there was resolution of signs and symptoms of the uUTI present at Baseline (and no worsening and no new signs and symptoms) and no requirement for the use of other antibacterial therapy. "Clinical Resolution Failure (CRF)" was defined when investigator's assessment was Clinically Unresolved/Clinical Worsening or Indeterminate at ToC. Indeterminate was defined as refusal to consent to a clinical examination or failure to attend the ToC visit.
| Participants | Nitrofurantoin + Placebo | GSK3882347+ Placebo |
|---|---|---|
| Clinical Resolution Success (CRS) | 11 | 21 |
| Clinically Unresolved (CU)/Clinical Worsening (CW) | 0 | 6 |
| Indeterminate (Ind) | 0 | 1 |
The investigators were asked to record their impression of the clinical status of the participant with regard to the presenting uUTI (resolved/unresolved). Clinical resolution response at FU was defined as "CRS" when investigator's assessment was Clinically Resolved at both ToC and FU (SCR), i.e., resolution of signs and symptoms of the uUTI present at BL (and no worsening and no new signs and symptoms) and no requirement for the use of other antibacterials. "CRF" was defined when investigator's assessment was: Clinically Unresolved at ToC but Clinically Resolved at FU (DCR); Clinically Resolved at ToC but Clinically Unresolved at FU (CRr); Clinically Unresolved at both ToC and FU (CU/CW); or when participants refused to consent to a clinical exam, failed to attend the FU, or achieved SCR/DCR but received other systemic antibacterials before FU (Ind).
| Participants | Nitrofurantoin + Placebo | GSK3882347+ Placebo |
|---|---|---|
| Clinical Resolution Success (CRS) | 10 | 19 |
| Delayed Clinical Resolution (DCR) | 0 | 3 |
| Clinical Recurrence (CRr) | 1 | 1 |
| Clinically Unresolved (CU)/Clinical Worsening CW) | 0 | 3 |
| Indeterminate (Ind) | 0 | 2 |
Collected over All-cause mortality and SAEs were collected from the signing of informed consent up to the Follow-up Visit (up to Day 31). Non-SAEs were collected from the first dose of study intervention up to the Follow-up Visit (up to Day 31).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nitrofurantoin + Placebo | 0/31 (0%) | 0/31 (0%) | 10/31 (32.3%) |
| GSK3882347+ Placebo | 0/91 (0%) | 0/91 (0%) | 22/91 (24.2%) |
| Event | Nitrofurantoin + Placebo | GSK3882347+ Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 2/31 | 7/91 |
| HeadacheNervous system disorders | 2/31 | 7/91 |
| AnaemiaBlood and lymphatic system disorders | 2/31 | 2/91 |
| Urinary tract infectionInfections and infestations | 0/31 | 4/91 |
| Abdominal painGastrointestinal disorders | 1/31 | 1/91 |
| Abdominal distensionGastrointestinal disorders | 1/31 | 0/91 |
| BacteriuriaInfections and infestations | 1/31 | 0/91 |
| Alanine aminotransferase increasedInvestigations | 1/31 | 1/91 |
| PollakiuriaRenal and urinary disorders | 1/31 | 1/91 |
| Vaginal dischargeReproductive system and breast disorders | 1/31 | 0/91 |
Randomized analysis set included all participants who passed screening, entered the study, and were randomly assigned to study intervention. Due to potential data quality issues, 14 participants were excluded from the analysis set.
| Age, Continuous(YEARS) | Nitrofurantoin + Placebo | GSK3882347+ Placebo | Total |
|---|---|---|---|
| Mean | 44.0 ± 14.89 | 45.6 ± 14.45 | 45.2 ± 14.52 |
| Sex: Female, Male(Participants) | Nitrofurantoin + Placebo | GSK3882347+ Placebo | Total |
|---|---|---|---|
| Female | 32 | 94 | 126 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Nitrofurantoin + Placebo | GSK3882347+ Placebo | Total |
|---|---|---|---|
| White | 28 | 78 | 106 |
| Black or African American | 3 | 11 | 14 |
| Asian | 1 | 4 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from May 2022 to primary completion in Dec 2024, 30 months.
Results were first posted in Mar 2026, 1 year 3 months after primary completion.
Of 16 phase 1 interventional studies under Urinary Tract Infections, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's 30 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK3882347